In vitro antiplasmodial activity and prophylactic potentials of extract and fractions of *Trema orientalis* (Linn.) stem bark

John Oludele Olanlokun¹*, Oluwole Moses David² and Anthony Jide Afolayan³

**Abstract**

**Background:** *Trema orientalis* (*T. orientalis* Linn) has been used in the management of malaria in the western part of Nigeria and despite its application in ethnomedicine, there is dearth of scientific evidence to justify the acclaimed prophylactic antimalarial usage of the plant. The aim of this study is to assess the in vitro antiplasmodial cell-free assay and chemopreventive efficacy of the methanol extract of the stem bark of *T. orientalis* and its fractions as a prophylactic regimen for malaria prevention. Also, the antimicrobial activities of the extract and the fractions were investigated.

**Method:** Vacuum liquid chromatography was used to obtain dichloromethane, ethylacetate and methanol fractions from the methanol extract of *T. orientalis*. The fractions were tested for their prophylactic and cell-free antimalarial activity using murine models and β-hematin formation assay respectively. Disc diffusion method was used to determine the antibacterial activity of the extract and its fractions against both Gram-positive and Gram-negative bacteria.

**Results:** In the prophylactic experiment, dichloromethane (DCMF), methanol fraction (MF) and extract (ME) (in this order) showed significant chemopreventive effects against *P. berghei* invasion of the red blood cells when compared with both Sulfadoxine-Pyrimethamine (SP) and untreated controls. Results of the in vitro study showed that the DCMF had the highest effect in preventing the formation of β-hematin when compared with other fractions. The DCMF also had the highest percentage inhibition of β-hematin formation when compared with chloroquine. The extract and fractions showed a concentration dependent antibacterial activity. Methanol extract had a pronounced inhibitory effect on *Enterobacter cloaca* ATCC 13047 and *Enterococcus faecalis* ATCC 29212. *Serratia mercescens* ATCC 9986 and *Pseudomonas aeruginosa* ATCC 19582 were the most susceptible bacteria.

**Conclusion:** The results obtained showed that both extract and fractions of *T. orientalis* possessed antiplasmodial and antimicrobial activity.

**Keywords:** Plasmodium bergei, Hemin, Hemozoin, Ferriprotoporphyrin (ix), *Trema orientalis*, Chloroquine, Sulfadoxine-pyrimethamine

* Correspondence: jodel72000@yahoo.com
1 Laboratories for Biomembrane Research and Biotechnology, Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Malaria is a febrile, mosquito-borne infection, which is responsible for symptoms like periodic chills, rigors, profuse sweating and high fevers, which occur at regular intervals of 48 to 72 h [1]. Malaria is a serious and often fatal disease caused by plasmodium parasite that is transfected when mosquito feeds on blood meal from humans. Despite the fact that malaria is a deadly disease, illness and death from malaria can usually be prevented [2]. The geographical distribution of malaria is determined by the distribution of the Anopheles mosquitoes, as well as areas having the correct climate. The transmission has traditionally remained at altitudes below 2000 m [3]. Recently, there has been increased malarial transmission in areas of higher altitudes in Africa, possibly due to the climatic change resulting in increased temperatures in high-altitude areas [4].

The incidence of severe malaria is very high among children below 5 years of age in malaria endemic areas. Patients with severe P. falciparum infections often have high parasite counts, and may develop severe symptoms from several organ systems [5].

Malaria's severity is noticed in children within a short time and this can degenerate further in hours with clinical features such as anaemia, cerebral malaria, hypoglycaemia, jaundice and respiratory distress [6]. Other clinical symptoms such as kidney failure, metabolic acidosis and high lactate levels have also been reported in severe malaria [7].

Cerebral malaria is one of the complications where the patient has reduced consciousness that can develop into coma or death. Clinical manifestations in relation to this include convulsions, reduced response to painful stimuli, abnormal motor posturing and increased intracranial pressure [8]. Severe hemolytic anaemia has also been associated with malaria infection [9]. This is so because erythrocytes are destroyed coupled with its minimal synthesis, depletion of folate and reduced red blood cell in circulation. The development of anaemia may be gradual or rapid and it may be chronic especially when the infections are persistent [10]. Malaria infection causes reduced blood glucose and this is responsible for high mortality rates among children and this, coupled with anemia and cerebral malaria, increase mortality rate [6]. It is not only P. falciparum specie that is responsible for most of the mortality from severe malaria, other species may progress in severity as well. For example, malaria caused by P. vivax is often responsible for respiratory symptoms, which may progress to coma. Malaria caused by P. vivax can also result in renal failure [11]. P. vivax has hypnozoites, which cause relapse of infection. These relapses make the chronic complications to malaria infections, such as anaemia, more severe.

Malaria parasites undergo a series of morphological transformations during their life cycle. Upon invasion of the human host, the parasites invades the liver; undergo maturation before being released into the bloodstream, starting yet another stage called the intraerythrocytic stage. During this stage, the malaria parasite multiplies and changes forms into what looks like a ring called the “ring stage” [12]. At this stage, the parasite degrades hemoglobin for its biosynthetic requirements, releasing free heme also known as Ferritroporphyrin (IX) (FePPIX) in the process [13]. Ferritroporphyrin (IX) is highly reactive and toxic to plasmodium which if allowed to accumulate, will cause the generation of Reactive Oxygen Species (ROS) which may induce oxidative stress leading to parasitic death [14]. To avoid the toxic effects of heme, trophozoite stage parasites polymerize these molecules within their food vacuole of an estimated pH between 4.5 to 5.0, into a non-toxic, un-reactive, insoluble crystalline compound called Hemozoin or “Malaria pigment”. Hemozoin formation thus is considered an important target in the search and finding of new antimalarial drugs [15, 16]. To mimic the exact environments and for further studies on hemozoin in vitro, a synthetic polymer structure made from Ferritroporphyrin (IX) named β-hematin is believed to be a structural analog of hemozoin, making it an excellent alternative for the purpose [17, 18].

In spite of several efforts to combat malaria through chemotherapy, vaccines or chemoprevention, the disease remain unabated simply because of the distribution, widespread and survival of the mosquitoes that carry the parasite and multidrug resistance of the parasite to different drugs designed to cure the disease. Again, variability in the developmental stages of the parasite has also made the treatment quite laborious simply because drugs designed for asexual stage of the parasite may not be therapeutically effective against the sexual stages. In Africa for example, poverty, strict adherence to treatment regimen to avoid resistance and exposure to mosquito are the major challenges faced in the eradication of the disease from the continent. As long as the infection and resistance to drugs continue unabated, search for total cure for the disease must also continue to completely eradicate malaria from the continent.

Several approaches had been developed in the treatment of the disease in Africa. One of the most prominent means is the folkloric approach using the herbs with plausible cure for the disease. Decoction prepared from these herbs is either taken for therapeutic purpose or for prevention. Tren\(a orientalis\) Linn Blume is one of such plant with promising antiplasmodial properties. It is a perennial tree that belongs to the family Ulmaceae. Almost every part of the plant is used for traditional medicine in Africa [19]. The stem bark decoction is used as vermifuge and anti-dyserteries [20] while the leaves are mixed with leaves of \(Bidens pilosa, Citrus aurantiifolia,\) and peels of unripe pineapple to treat jaundice, bronchitis, pneumonia and pleurisy [21], the bark...
and leaf decoction has been reported to have antiplasmodial activities [22]. In Nigeria, the stem bark is peeled and soaked in water or soaked with other plant for drinking and bathing to treat malaria [23, 24]. Our previous experiment on the curative effect of this plant further validated the therapeutic efficacy of the plant [31] and also necessitated our quest for the chemopreventive effect of this same plant extract against malarial infection. Other authors have established the various drug potential [25] and specifically, curative effects of this plant extracts on plasmodium malaria [26]. A previous study had reported that T. orientalis had in vitro antiparasitic activity [27]. The animal model (mice) was used in this research because the plasmodium strain (P. berghei) develops in the mouse model and because they are lower mammals, possible extrapolation to human biology may be possible to some extent. If truly effective and without prominent side effects, drug candidates can be purified and optimized from this herb and by so doing, complete cure and prevention for the disease is possible. Premised on this fact, we investigated the in vivo chemopreventive effects and the in vitro antiplasmodial activity of the stem bark extract and fraction of T. orientalis on P. berghei-induced malaria in mice.

Methods

Plant source, identification and preparation of solvent extract and fractions

The plant was identified and authenticated in their fresh state by Mr. Omotayo, F.O., the present curate of the Herbarium Unit of Plant Science Department of the Faculty of Science, Ekiti State University, Nigeria. A specimen is domiciled in the Unit and registered with the Identification Number UHAE 2015/35. The stem bark peels of T. orientalis were obtained from Ado-Ekiti, Nigeria in March, 2016. The collection site was wild and as a result, did not require authorization from anybody. The stem bark peels were air-dried at room temperature to avoid possible degradation or denaturation of their active compounds. The air-dried stem bark was blended to powder using an electric blender. This was stored in a glass container. Thereafter, 5 kg of blended air-dried stem bark was soaked in 10 L of methanol for 72 h at room temperature. It was continually stirred after each 24 h. After 72 h, the mixture was filtered and the filtrate was concentrated using rotary evaporator under reduced pressure at 40 °C. The crude methanol extract concentrate weighed 53 g.

Vacuum liquid chromatography purification procedure

The crude methanol extract was further purified using the Vacuum Liquid Chromatography (VLC). The pre-washed sintered glass Buchner was further cleaned with concentrated H₂SO₄ to remove impurities from the sieve. The column was then packed three-quarter full with silica gel 60 (0.040–0.063 mm, MERCK). The column was then placed on a conical flask Buchner and connected to the vacuum pump. The crude methanol extract (20 g) was adsorbed to 20 g of the Thin Layer Chromatography gel (particle size 0.040–0.063 mm). The column was packed with n-hexane and the adsorbed sample was applied to the column, the pump was switched on and adsorbed sample was washed first with n-hexane solvent, topically applied to the column, then successively with dichloromethane, ethylacetate and finally with methanol. The fractions obtained were concentrated at 40 °C using rotary evaporator and transferred into pre-weighed all-glass sample bottles with rubber stopper and labeled.

Prophylaxis experiment

Thirty male Swiss albino mice (15 g) were obtained from the animal house section of the Institute of Advanced Medical Research And Training (IAMRAT), College of Medicine, University of Ibadan, grouped into six groups of five animals each and were acclimatized for two weeks with regular feeding with rat chow and clean water. The animals were kept in clean cages with wooden shaves as beddings in the animal house under 12 dark/light cycle. The animals were randomly assigned into the groups; four experimental groups of five animals each for the test drugs and two control groups of five animals each. The negative control group receive vehicle only while the positive control group received standard drug only.

After acclimatization, the animals were orally pre-treated once daily with a daily dose of 50, 100 and 200 mg per kg body weight of methanol extract (ME), methanol (MF), dichloromethane (DCMF), and ethyl acetate (EF) fractions, vehicle and 10 mg per kg body weight of Sulfadoxine-pyrimethamine (SP) which is the standard drug for 1 week before they were transsected with infected erythrocytes from a donor mouse using an inoculums size of 10⁷ of the parasite load of chloroquine-sensitive strain of P. berghei. The negative control group animals were treated with the vehicle (5% Dimethylsulfoxide (DMSO). Treatment of all the test and control groups were done daily (orally), continued throughout the experiment and thin film slides were collected once in 2 days until day seven of the experiment. Microscopy was carried out with the aid of binocular microscope (Olympus brand) using oil immersion objective. The percentage parasitemia and percentage clearance were used to assess the antiplasmodial efficacy of the drug candidates.

After the seventh day, blood was collected from the animal and were used for the assessment of the Packed Cell Volume (PCV), White Blood Cell (WBC) count and Full Blood Count (FBC).

Percentage Parasitemia and percentage parasite clearance where calculated as follows:
Percentage Parasitemia = Number of infected Red Blood Cells counted X 100 / Total Number of Red Blood cells counted X 100

Percentage Clearance = \frac{Control - Test}{Control} \times 100

In vitro antiplasmodial cell-free assay

Antimalarial activity of \textit{T. orientalis} extract and fractions was evaluated by the method described by Afshar et al. [28] with some modifications. Briefly, varying concentrations (10–80 mg/mL) freshly dissolved in dimethyl sulphoxide (DMSO) of the extracts and fractions were produced. The reaction mixtures were incubated with 50 μL of 60 mM hemin chloride, 250 μL of 40 mM oleic acid, and 250 μL of 4 M HCl. The final volume was adjusted to 1.0 mL volume using varied volumes of sodium acetate buffer, pH 5, for eighteen h at 37 °C in a shaker water bath. Artesunate and Chloroquine diphosphate were used as positive controls. After incubation, the samples were centrifuged (14,000 rpm, 10 min, at 21 °C) and the hemozoin pellet was repeatedly washed with incubation (15 min at 37 °C with regular shaking) in 2.5% (w/v) SDS in phosphate buffered saline followed by a final wash in 0.1 M sodium bicarbonate until the supernatant was clear (usually 3–8 washes). After the final wash, the supernatant was discarded and the pellets were dissolved in 1.0 mL of 0.1 M NaOH before determining the hemozoin content by measuring the absorbance at 400 nm (752 N BOSCH UV-VIS spectrophotometer). The results were recorded as % inhibition (%) of heme crystallization compared to negative control (DMSO) using the following equation:

\[ I\% = \frac{(AN - AS)}{AN} \times 100 \]

where, \( AN \) is absorbance of negative control and \( AS \) is absorbance of test samples.

Antibacterial activity of the extract and fractions of \textit{T. orientalis}

The bacteria used in this study were collected from the Department of Microbiology Laboratory, Ekiti State University, Ado-Ekiti, Nigeria. The organisms include four Gram negative bacteria (\textit{Enterobacter cloaca} ATCC 13047, \textit{Escherichia coli} ATCC 8739, \textit{Serratia mercescens} ATCC 9986 and \textit{Pseudomonas aeruginosa} ATCC 19582) and two Gram positive bacteria (\textit{Enterococcus faecalis} ATCC 29212 and \textit{Staphylococcus aureus} ATCC 6538). The test bacteria were grown at 37 °C in Mueller-Hilton broth (Oxoid) for 16–18 h and turbidity adjusted to 0.5 McFarland Standard (optical density of 0.1 at wavelength of 625 nm) and stored at 4 °C. The bacterial suspension was further diluted 1:100 to achieve a working suspension of 10^6 CFU/mL. The extract and the fractions were dissolved in 5.0% DMSO to achieve varying concentrations (1.563 to 50.0 mg/mL). Each of the concentration was impregnated into sterile 6 mm Whatman No. 1 filter paper disc. The disc was placed on Mueller Hinton Agar seeded with the test organism and incubated for 24 h at 37 °C. The diameter of inhibition of the test organism was recorded and the zone of inhibition was calculated according to the method of Aderiye and David [29].

Statistical analysis

Data were presented as mean ± Standard Deviation of triplicate determination. Statistical analysis was done using SPSS (version 17) to analysis of variance (ANOVA) and Dunn’s Multiple Comparisons Test. The level of significance was set at 0.05.

Results

Figure 1 showed the prophylactic effects of the methanol fraction on the percentage parasitemia (Fig. 1a) and percentage clearance (Fig. 1b). The percentage parasitemia decreased as the dose increased while the parasite clearance increased as the dose increased. Percentage parasitemia of the treated animals in 200 mg/kg body weight group decreased significantly from day 3 to seven when compared with the untreated control. Again, the percentage parasite clearance increased significantly in the animals under the same dosage group when compared with the untreated control.

In Fig. 2, the efficacy of the dichloromethane fraction (DCMF) of the methanol extract of \textit{T. orientalis} as a chemopreventive drug candidates for malaria infection was presented. The figure representing the percentage parasitemia (Fig. 2a) showed that the parasite count decreased as the dose increased with the least parasitemia obtained at the highest dose administered. The results obtained also showed that all the doses used in this work compared favourably with SP with 200 mg being the dose that has the highest percentage clearance (Fig. 2b).

In Fig. 3, it was shown that the ethylacetate fraction had the least efficacy as it had the highest percentage parasitemia even in the highest dose used (Fig. 3a) and the least parasite clearance as depicted in Fig. 3b. The chemopreventive effects of the methanol fraction as a potential prophylactic regimen for the prevention of malaria infection were presented in Fig. 4.
results obtained showed that the percentage parasitemia decreased (Fig. 4a) but zero parasitemia was not obtained when compared with SP. The percentage parasite clearance also was about 70% at the highest dose used (Fig. 4b).

Table 1 below explained that, at the lowest dosage of the extract (50 mg), the packed cell volume, white blood cell, neutrophil and lymphocyte of the extract were significantly higher than the control. Dichloromethane showed the highest value in these parameters having a packed cell volume of 40, white blood cell count of 7.95, neutrophil of 35 and lymphocyte of 60.5, which is an indication that it is more effective than the other drug candidates. These values are higher in comparison to the lowest dosage of the extract as explained in Table 1 therefore; the extract and fractions showed a higher level of effectiveness as the dosage increased.

At 100 mg dosage of the extract, the packed cell volume, white blood cell, neutrophil and lymphocyte values of the extract were significantly higher than the control. Dichloromethane showed the highest value in these parameters having a packed cell volume of 41, white blood cell count of 8, neutrophil of 35 and lymphocyte of 55.5, which is an indication that it is more effective than the other drug candidates. These values are higher in comparison to the lowest dosage of the extract as explained in Table 1 therefore; the extract and fractions showed a higher level of effectiveness as the dosage increased.

At the highest dosage of the extract and fractions, the hematological parameters including packed cell volume, white blood cell, neutrophil and lymphocyte presented values that were considerably higher than the control whereas dichloromethane showed the highest values of 42, 10.2, 38 and 67 in each of them respectively. This therefore is an indication that dichloromethane is more effective than the other drug candidates at the highest dosage. Again, SP showed a higher value in these parameters than dichloromethane.

The results of the in vitro antiplasmodial activity of the extract and fractions of T. orientalis are shown in Fig. 5 in comparison to two positive controls (both chloroquine and artesunate). The absorbance of the
samples (400 nm) is inversely proportional to drug efficacy; the lower the absorbance, the more efficient the drug is. Although, all the drug candidates inhibited β-hematin formation, it is quite interesting to note that the dichloromethane fraction is the most potent fraction and is more effective than chloroquine phosphate.

As shown in Table 2; the extract and fractions of *T. orientalis* showed a concentration dependent antibacterial activity; meaning that the activity was higher at the highest concentration than at lower concentrations. In this antibacterial assay, methanol extract had a pronounced inhibitory effect on *Enterobacter cloaca* ATCC 13047 and *Enterococcus faecalis* ATCC 29212 while methanol fraction had the best inhibitory effects on *Escherichia coli* ATCC 8739 and *Serratiamercescens* ATCC 9986. The extract and the fractions affected both Gram-positive and Gram-negative bacteria alike thus, the susceptibility of the isolates to the extract and the fractions is as follows; *Serratiamercescens* ATCC 9986 < *Pseudomonas aeruginosa* ATCC 19582 < *Escherichia coli* ATCC 8739 < *Enterococcus faecalis* ATCC 29212 < *Enterobacter cloaca* ATCC 13047 < *Staphylococcus aureus* ATCC 6538. All the drug candidates screened performed lower than the Control 10 μg/mL gentamicin. Methanol extract had the highest inhibitory effect on *Enterobacter cloaca* followed by methanol fraction while ethylacetate fraction had the least effects on the isolate. The antibacterial activity of the extract and the fractions had no significant difference when compared at *P* 0.05.

**Discussion**

The quest for cost effective and efficacious antimalarial drugs has made search for antiplasmodial drugs unending. The use of plant-based medicines for the treatment and prevention of malaria remain important in rural areas in Nigeria and probably other parts of Africa. This is partly because of the high cost of the patented drugs and unavailability of orthodox medicine in rural areas. In some areas in Africa, it is believed that herbs work better than the orthodox medicine. As a result of this, many herbs of plausible antimalarial properties had been...
authenticated and documented for their efficacy. *T. orientalis* is used as an antimalarial herb locally in Nigeria but this herb decoction and others used for the prevention of malaria purposes are usually taking daily and without a specific regimen. In folkloric medicine, such herbs that are usually taking as antimalarial prophylactics are *Enantia chloranta*, *Alstonia boonei*, etc. Apart from Nigeria, in Zimbabwe for example, local dwellers rely mostly on some herbs such as *Momordica balsamina L.* (leaf), *Momordica foetida Schumach* (leaf)

Table 1 The hematological parameters of *P. berghei*-infected mice pretreated with various extracts of *T. orientalis*

| Dose (mg/body weight) | Extract       | PCV % | WBC% | Neutrophil | Lymphocyte | Monocyte | Eosinophil | Basophil |
|-----------------------|---------------|-------|------|------------|------------|----------|------------|---------|
| 50                    | MEOH FR       | 30    | 6.00 | 33         | 53.5       | 1.5      | -          | -       |
|                       | DCM           | 40    | 7.95 | 35         | 60.5       | 01       | 0.5        | -       |
|                       | MEOH EX       | 33    | 6.65 | 34         | 58.5       | 0.5      | -          | -       |
|                       | ETOAC FR      | 28.5  | 5.35 | 30         | 50         | 01       | -          | -       |
|                       | SP            | 43    | 6.4  | 34.5       | 65         | -        | -          | -       |
|                       | VEHICLE       | 30    | 5.6  | 32         | 48         | -        | -          | -       |
| 100                   | MEOH FR       | 32.5  | 7.25 | 35         | 55.5       | 02       | 01         | 0.5     |
|                       | DCM           | 41    | 8.00 | 36.5       | 65         |          |            |         |
|                       | MEOH EX       | 35    | 7.35 | 36         | 59         | -        | -          | -       |
|                       | ETOAC FR      | 30    | 6.8  | 34         | 53         | -        | -          | -       |
|                       | SP            | 43    | 6.4  | 34.5       | 65         | -        | -          | -       |
|                       | VEHICLE       | 30    | 5.6  | 32         | 48         | -        | -          | -       |
| 200                   | MEOH FR       | 35    | 7.4  | 35.5       | 59         | 01       | -          | -       |
|                       | DCM           | 42    | 10.2 | 38         | 67         | 01       | -          | -       |
|                       | MEOH EX       | 38    | 8.00 | 36         | 61         |          |            |         |
|                       | ETOAC FR      | 32.5  | 7.8  | 35         | 55         | -        | -          | -       |
|                       | SP            | 43    | 6.4  | 34.5       | 65         | -        | -          | -       |
|                       | VEHICLE       | 30    | 5.6  | 32         | 48         | -        | -          | -       |

**KEY:** MEOH FR Methanol Fraction, DCM FR Dichloromethane Fraction, MEOH EX Methanol Extract, ETOAC FR Ethylacetate Fraction, SP Sulfadoxine-pyrimethamine

Fig. 5 Percentage inhibition of β-hematin formation between extracts and fractions of *T. orientalis* and the standard controls. Key: ME = Methanol Extract, CM = Dichloromethane fraction, EA = Ethylacetate fraction, MF = Methanol Fraction, Chlqn = Chloroquine, Artsnt = Artesunate
and *Adeniacis sampeloides* (Planch exHook) Harms (root) which are all used mainly as prophylactic regimen for malaria [30].

We are of the opinion that if such preparations worked without adverse effects, it is far better than therapeutic approach after an established infection of malaria. However, in areas where these herbs are taking either for treatment or prophylactic purposes, dose preparation is always a problem because herbal preparation is always taken ad libitum. This habit however can predispose the patients to the toxic effects of the secondary metabolites from the herbs.

From the results presented, it could be seen that the DCMF fraction had a good prophylactic effects in preventing malarial infection. This is because it suppressed the invasion of the Red Blood Cells (RBC) by the malaria parasites. Olanlokun [31] and his coworkers had shown that the DCMF fraction of this plant had the highest therapeutic antimalarial properties. It is quite interesting to note also, that this same fraction had the best chemopreventive properties against malaria parasite invasion. The GC-MS analysis of this fraction had shown the presence of fatty acid methyl esters. Several plant derived antimalarial agents have been identified. Alkaloids [32, 33] and non alkaloid natural products such as terpenes [34, 35], flavonoids, chromones, xanthes, anthraquinones and related compounds [36–41] had been well documented. However, miscellaneous

| Test Organisms | Extract/Fraction | Concentrations (mg/mL) |
|----------------|------------------|------------------------|
|                |                  | 50.000 | 25.000 | 12.500 | 6.250 | 3.125 | 1.563 |
| Enterobacter cloaca ATCC 13047 | Ethylacetate fraction | 35.54 ± 8.34 | 18.62 ± 3.54 | 0.00 | 0.00 | 0.00 | 0.00 |
|                  | Dichloromethane fraction | 58.24 ± 12.40 | 38.50 ± 11.74 | 3.14 ± 1.01 | 0.00 | 0.00 | 0.00 |
|                  | Methanol Extract | 102.14 ± 23.45 | 54.29 ± 10.81 | 7.07 ± 1.45 | 3.14 ± 1.32 | 0.00 | 0.00 |
|                  | Methanol Fraction | 48.69 ± 6.01 | 50.29 ± 9.33 | 12.57 ± 4.30 | 0.00 | 0.00 | 0.00 |
|                  | Gentamicin (10 μg/mL) | 211.13 ± 9.25 | 211.13 ± 9.25 | 211.13 ± 9.25 | 211.13 ± 9.25 | 211.13 ± 9.25 | 211.13 ± 9.25 |
| Escherichia coli ATCC 8739 | Ethylacetate fraction | 50.29 ± 12.37 | 56.30 ± 11.80 | 28.29 ± 3.72 | 7.07 ± 3.23 | 0.00 | 0.00 |
|                  | Dichloromethane fraction | 66.24 ± 8.26 | 48.19 ± 9.83 | 32.73 ± 2.92 | 22.29 ± 1.56 | 0.00 | 0.00 |
|                  | Methanol Extract | 52.21 ± 9.36 | 35.50 ± 10.10 | 28.40 ± 3.30 | 12.57 ± 3.84 | 3.14 ± 0.44 | 0.00 |
|                  | Methanol Fraction | 71.53 ± 32.23 | 44.92 ± 8.54 | 19.14 ± 1.95 | 19.34 ± 0.85 | 3.14 ± 1.93 | 0.00 |
|                  | Gentamicin (10 μg/mL) | 144.52 ± 3.87 | 144.52 ± 3.87 | 144.52 ± 3.87 | 144.52 ± 3.87 | 144.52 ± 3.87 | 144.52 ± 3.87 |
| Serratiamercescens ATCC 9986 | Ethylacetate fraction | 93.07 ± 6.12 | 73.12 ± 5.27 | 78.57 ± 16.34 | 7.07 ± 2.56 | 0.00 | 0.00 |
|                  | Dichloromethane fraction | 142.09 ± 15.28 | 95.07 ± 7.23 | 78.57 ± 10.67 | 52.21 ± 3.83 | 12.57 ± 3.45 | 3.14 ± 0.45 |
|                  | Methanol Extract | 63.64 ± 9.34 | 63.64 ± 9.34 | 0.00 | 0.00 | 0.00 | 0.00 |
|                  | Methanol Fraction | 79.57 ± 8.10 | 96.07 ± 15.28 | 63.64 ± 3.67 | 61.45 ± 6.44 | 0.00 | 0.00 |
|                  | Gentamicin (10 μg/mL) | 111.13 ± 3.16 | 111.13 ± 3.16 | 111.13 ± 3.16 | 111.13 ± 3.16 | 111.13 ± 3.16 | 111.13 ± 3.16 |
| Pseudomonas aeruginosa ATCC 19582 | Ethylacetate fraction | 64.31 ± 4.19 | 58.64 ± 7.28 | 53.29 ± 5.23 | 19.64 ± 2.45 | 3.83 ± 0.45 | 0.00 |
|                  | Dichloromethane fraction | 65.07 ± 24.34 | 28.29 ± 6.26 | 3.14 ± 0.34 | 0.00 | 0.00 | 0.00 |
|                  | Methanol Extract | 73.57 ± 12.33 | 50.29 ± 9.28 | 38.50 ± 11.36 | 4.56 ± 1.04 | 0.00 | 0.00 |
|                  | Methanol Fraction | 113.14 ± 23.12 | 63.64 ± 7.29 | 19.64 ± 2.45 | 3.14 ± 0.77 | 0.00 | 0.00 |
|                  | Gentamicin (10 μg/mL) | 356.50 ± 12.07 | 356.50 ± 12.07 | 356.50 ± 12.07 | 356.50 ± 12.07 | 356.50 ± 12.07 | 356.50 ± 12.07 |
| Enterococcus faecalis ATCC 29212 | Ethylacetate fraction | 122.79 ± 13.60 | 50.29 ± 13.92 | 19.64 | 3.36 ± 1.35 | 3.19 ± 0.31 | 0.00 |
|                  | Dichloromethane fraction | 38.50 ± 7.27 | 32.50 ± 4.65 | 12.57 | 0.00 | 0.00 | 0.00 |
|                  | Methanol Extract | 81.81 ± 5.73 | 28.29 ± 7.12 | 19.64 | 3.14 ± 0.25 | 0.00 | 0.00 |
|                  | Methanol Fraction | 52.19 ± 7.45 | 38.50 ± 3.71 | 38.50 | 0.00 | 0.00 | 0.00 |
|                  | Gentamicin (10 μg/mL) | 165.20 ± 14.02 | 165.20 ± 14.02 | 165.20 ± 14.02 | 165.20 ± 14.02 | 165.20 ± 14.02 | 165.20 ± 14.02 |
| Staphylococcus aureus ATCC 6538 | Ethylacetate fraction | 52.19 ± 9.15 | 28.29 ± 3.27 | 29.29 ± 3.18 | 19.84 ± 3.23 | 3.18 ± 0.31 | 3.11 ± 0.23 |
|                  | Dichloromethane fraction | 53.82 ± 9.38 | 24.23 ± 3.55 | 0.00 | 0.00 | 0.00 | 0.00 |
|                  | Methanol Extract | 50.29 ± 18.39 | 28.49 ± 7.23 | 19.64 ± 3.91 | 0.00 | 0.00 | 0.00 |
|                  | Methanol Fraction | 53.23 ± 7.14 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|                  | Gentamicin (10 μg/mL) | 50.29 ± 4.45 | 50.29 ± 4.45 | 50.29 ± 4.45 | 50.29 ± 4.45 | 50.29 ± 4.45 | 50.29 ± 4.45 |
compounds such as cyclic alkyl polyol derivatives and benzoic acid derivatives have also been shown to exhibit a relatively good antiplasmodial activity [42].

Innate immunity is an ancient and highly conserved system that provides a first line of defense against infection [43]. Immune cells such as monocyte/macrophages, natural killer (NK) cells, neutrophils, mast cells, dendritic cells (DCs), and certain T cell subsets, as well as epithelial and endothelial cells, sense the presence of pathogens or the tissue damage they cause, and respond by elaborating chemical signals (cytokines and chemokines). These pro-inflammatory mediators recruit and activate immune cells to destroy pathogens using various effector mechanisms, such as phagocytic clearance, production of reactive oxygen and nitrogen species, and secretion of anti-microbial peptides.

Phagocytosis of parasitized erythrocytes (PEs) and merozoites by myeloid cells is thought to be a primary mechanism for parasite clearance in non-immune individuals. Monocyte/macrophages and neutrophils have been shown to phagocytose PEs in vitro in the absence of malaria-specific antibodies [44, 45]. Other innate immune components contribute to control of malaria infection, such as PE destruction by platelets [46]. Parasites are also sensitive to oxidative stress: administration of pro-oxidants reduced parasitemia in Plasmodium vinckei infection [47]. Whether phagocyte production of reactive oxygen species (ROS) and nitric oxide (NO) contributes to control of parasite replication is controversial. Phagocyte-derived ROS and NO were shown to kill parasites in vitro [48, 49] and ex vivo neutrophil ROS production inversely correlated with parasite clearance time in Gabonese children [50]. If an increase in these blood cells minimize or at best control malaria parasite infection then, an increase in the production of these blood cells may be beneficial in defense mechanism. It is therefore not surprising that neutrophils, lymphocytes, monocytes, eosinophils and basophils increased in the group treated with DCM fraction of T. orientalis. Leucopenia was frequently seen in the malaria-infected animals that were not treated which was confirmed by other studies [51]. Anemia is one of the most common complications in malaria infection. This is because the infected blood cell membrane ruptured thus leading to hemolytic anemia. Low Packed Cell Volume (PCV) equally causes low hemoglobin content. Treatment with DCM fraction significantly increased the PCV and hemoglobin content compared with the untreated control and other drug candidates.

The intra-erythrocytic stage of malaria parasite is very important and is highly fundamental to the life cycle of this organism. This is because massive degradation of hemoglobin after a blood meal results in the liberation of monomeric heme which is highly toxic to the parasite. In order to survive, this parasite, as other blood parasites, have evolved a unique mechanism for heme detoxification through its conversion into an unreactive, nontoxic, insoluble crystalline pigment, known as hemozoin [52]. Disruption of this crystallization process results in the accumulation of this toxic molecule leading to the generation of Reactive Oxygen Species (ROS) which may induce oxidative stress consequently leading to the death of the parasite. Thus, this important stage serves as a target for action of several known antimalarial drugs [53, 54]. Also it is an excellent target for biochemistry studies and drug design in such a way that any drug candidate that can inhibit the formation of β-hematin can induce heme toxicity in the organism and so, parasite death occurs.

The in vitro antiplasmodial activity of the extract and fractions of T. orientalis showed that the DCM fraction had the highest inhibitory effect on β-hematin formation. The results obtained also showed that the DCM fraction compared favourably with artesunate and inhibit β-hematin formation better than chloroquine of the same concentration. The ability of this fraction to inhibit β-hematin formation significantly higher than chloroquine is highly appreciated while the ethylacetate fraction had the least activity. In the same vein, the extracts at high concentrations have inhibitory effects on both Gram-negative and Gram-positive bacteria.

Different parts of plant materials have been reported to exhibit anti-bacterial activities [55–57] Antibacterial compounds like octacosanoic acid, 1-octacosanyl acetate, simiarenone, simiarenol, episimiarenol and trematol have been isolated from stem bark of the plants [58]. Methanol extract had a pronounced inhibitory effect on the test isolates. This supported the report of Uddin [59] who reported ethanol extract of T. orientalis to be effective against both Gram-negative and Gram-positive bacteria. The activity of the plant may be due to the phytochemical constituents of the plant which justify its ethno medicinal usage among the rural dwellers [60].

From this study, it can be seen that various solvent preparations of the stem bark of T. orientalis were effective against malaria parasite thus, supporting the antiplasmodial indigenous claim of this plant. An improvement on the decoction preparation will be beneficial because most antimalarial indigenous claim of this plant. An improvement on the decoction preparation will be beneficial because most antimalarial herbs are locally extracted with water or other aqueous media.

Conclusion
We hereby conclude that this work further substantiate the folkloric antimalarial and antibacterial use of this plant scientifically. In addition, we will suggest that the extraction procedures and solvent used be reviewed because the dichloromethane fraction was the most potent and locally, aqueous extraction is employed. It was again showed that the probable mechanism for the
antiplasmodial effect was revealed to be via the heme metabolism in the malaria parasite.

**Abbreviations**

ANOVA: Analysis of variance; ARDS: Acute respiratory distress syndrome; CFU: Colony forming unit; DCMF: Dichloromethane fraction; DCMF and DCMC: Dichloromethane Fraction Percentage Parasitemia and Clearance; DCs: Dendritic Cells; DMSO: Dimethylsulphoxide; EAP and EAC: Ethylacetate Fraction Percentage Parasitemia and Clearance; EF: Ethylacetate fraction; FePPX: Ferriproteinphorphyrin IX; ME: Methanol extract; MFP and MEC: Methanol Extract Percentage Parasitemia and Clearance; MF: Methanol fraction; MFP and MFC: Methanol Fraction Percentage Parasitemia and Clearance; NK: Natural Killer; NO: Nitric Oxide; P. falciparum: Plasmodium falciparum; P berghei: Plasmodium berghei; PCV: Packed Cell Volume; PES: Parasitized Erythrocytes; RDS: Reactive Oxygen Species; SDS: Sodiumduodecylsulphate; SP: Sulfadoxine-pyrimethamine; T. orientalis: Trema orientalis; UHAE: University Herbarium, Ado-Ekiti; VLC: Vacuum Liquid Chromatography; WBC: White Blood Cell

**Acknowledgments**

The authors acknowledge Mr. F.O. Omotayo of the University Herbarium, Ekiti State University for the identification and authentication of the plant used in this work.

**Funding**

The financial burden of this work was borne exclusively by the authors.

**Availability of data and materials**

Data and materials were made available only by the authors.

**Authors’ contributions**

JOO carried out the prophylactic potentials of the test drugs on *P. berghei*-induced malaria in mice and the antiplasmodial cell-free assays. The overall researchable idea was conceived by OMD. He designed and carried out the prophylactic potentials of the test drugs on *P. berghei*. 

**Ethics approval and consent to participate**

All procedures that were used in this study conformed to the guidelines of the care and use of animals in research and teaching of the National Institute of Health (NIH) and according to the 1996 revised version.

**Consent for publication**

All authors consented to the publication of this article and were so informed before and after the submission of this article.

**Competing interests**

The authors declared that they have no competing interests.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1Laboratories for Biomembrane Research and Biotechnology, Department of Biochemistry, Faculty of Basic Medical Sciences, College of Medicine, University of Ibadan, Ibadan, Nigeria. 2Department of Microbiology, Faculty of Science, Ekiti State University, Ado-Ekiti, Nigeria. 3Medicinal Plants and Economic Development Research Centre, Botany Department, University of Fort Hare, Alice 5700, South Africa.

**Received:** 16 March 2017 **Accepted:** 7 August 2017

**Published online:** 15 August 2017

**References**

1. Johns HB. About malaria. Johns Hopkins Malaria Institute. 2015;
2. Centre for Disease Control and Prevention, about malaria, 2012.
3. Kumar S, Guha M, Choubey V, Maiti P, Bandypadhyay U. Antimalarial drugs inhibiting hemocyanin (beta-hematin) formation: a mechanistic update. Life Sci. 2007;80(9):813–28.
4. McMichael AJ. Climate change and human health: risks and responses. Geneva: WHO; 2003. p. 322.
5. Crawford J, Chu C, Mtove G, Nosten F. Malaria in children. Lancet Pub Med. 2010;24:1468–81.
6. World Health Organization. Clinical, behavioural and socioeconomic factors related to severe malaria: a multicenter study in the Africa region, WHO AFRO. 2002.
7. Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ong’echa JM. Severe malarial anemia: innate immunity and pathogenesis. Int J Biol Sci. 2011;7(9):1247–8.
8. World Health Organization. Management of severe malaria: a practical handbook. 2012.
9. Calis JC, Phiri KS, Faragher EB, Brabin BJ, Bates I, Cuevas LE. Severe anemia in Malawian children. New Engl J Med. 2008;358(9):888–99.
10. World Health Organization, Iron deficiency anaemia: assessment, prevention and control: a guide for programme managers. 2001.
11. Anstey NM, Russell B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol. 2009;25(5):220–7.
12. Pagola S, Stephens D, Kosar A, Madsen S. The structure of malaria pigment β-hematin. Nature. 2000;404:307–10.
13. Rathore D. Strategies for malaria control VBl Scientific. Ann Rev. 2006. p. 49–53.
14. Kumar PJP, and Clark ML. Kumar and Clark’s clinical medicine. Elsevier Science, Health Science Division. 7th edition. 2009.
15. Slater AF, Swiggard WI, Orton BR, Flitter WD, Goldberg DE, Cerami A, et al. An iron-carboxylate bond links the heme units of malaria pigment. P Nat Acad Sci USA. 1991;88(2):325–9.
16. Sullivan D. Hemoglobin, a biocatalyst synthesized during the degradation of hemoglobin. The Malaria Research Institute, Johns Hopkins University. 2000;9:129–37.
17. Blauer G, Akkawi M. On the preparation of β-hematin. Biochem J. 2000;346:249–50.
18. Blauer G, Akkawi M. Investigations of band β-hematin. J Inorg Biochem. 1997;66(2):145–52.
19. Yanes OV. Germination of a pioneer tree from equatorial Africa. Turrialba. 2007;27:301–2.
20. Githens TS. African handbooks. Vol. 8. Lancaster: United States: University of Pennsylvania Press; 1948. Drug plants of Africa; p. 125.
21. Katende AB. Useful trees and shrubs for Uganda. Identification, propagation and Management for Agricultural and Pastoral Communities. Regional Soil Conservation Unit (RSCU), Swedish International Development Authority (SIDA); 1995.
22. Orwa C, Mutua A, Kindt R, Jarmnadas R, Simons A. Agroforestree database: a tree reference and selection guide version 4.0, 2009.
23. Odugbemi TO, Akinsulire OR, Aibinu IE, Fabeku PO. Medicinal plants useful for malaria therapy in Okeigbo. Ondo state, south West Nigeria. Afr J Compl Alt Med. 2007;4(2):191–8.
24. Ofurunniyi OF, Morenikeji OA. The extent of use of herbal medicine in malaria management in Ido/Osi local government area of Ekiti state Nigeria. J Med Pl. 2013;7(4):3171–8.
25. Michael BA, Isaac KG, Nicholas OA. Trema orientalis Linn. Blume: a potential for prospecting for drugs for various uses. Pharm Rev. 2013;7(3):667–72.
26. Samuel B, Oluwem YW, Abioud C. Bioguided investigation of the antimalarial activities of Trema orientalis (L) Blume leaves. A J Biotech. 14(43):2966–71.
27. Abiodun OD, Gbotohso GO, Ajayeoba EO, Brun R, Oduola AM. Antitrypanosomal activity of some medicinal plants from Nigerian ethnmedicine. Parasitol Res. 2012;110(2):521–6.
28. Afshari FH, Delazer A, Janneh O, Nazemiyeh H, Pasdaran A, Nahar L, et al. Evaluation of antimalarial, free-radical scavenging and insecticidal activities of Artemisia scoparia and A. spicaeval, Asteraceae. Braz J Pharm. 2011;6:986–90.
29. Aderiye BI, David OM. In vitro antibacterial activity of aqueous extracts of cashew (Anacardium occidentale L) fruit peels using bioautography method. Eur J Med Pl. 2014(43):284–91.
30. Ngarihume T, van’t Klooster CEA, de Jong JTW, VanderWesthuizen JH. Medicinal plants used by traditional healers for the treatment of malaria in the Chibone district in Zimbabwe. J Ethnopharmacol. 2015;159(22):234–37.
31. Olanlokun O, David M, Ilori T, Abe V. In vivo antiplasmodial activity of extract and fractions of Trema orientalis in P. berghei-induced malaria in mice. J Coast Life Med. 2016;4(10):784–90.
32. Federich M, Titi M, Angenot L. Potential antimalarial activity of indole alkaloids. Trans R Soc Trop Med Hyg. 2008;102:11–9.
33. Oliveira AB, Dolabela MF, Braga FC, Jácome RLRP, Varotti FP, Póvoa MM. Plant-derived antimalarial agents: new leads and efficient phytomedicines. Part 1: Alkaloids. Ann Braz Acad Sci. 2009; In press.

34. Elange SM, Brum R, Wittlin S, Connolly JD, Hoyre TR, McAmat T, et al. Okunoderoxidperoxide, a bicyclic cyclofenamethyloxygaweroperoxidperoxide from Scienciastrinunwirr with antiplasmodial activity. J Nat Prod. 2009;72:280–3.

35. Murata T, Miyase T, Muregi FW, Naochina-Ishibashi Y, Umehara K, Warashina T, et al. Antiplasmodial triterpenoids from Ekebergia capensis. J Nat Prod. 2008;71:167–74.

36. Khawneek P, Ichino C, Ishyama A, Sekiguchi H, Namatame N, Ruangrungsi N, et al. In vitro antimalarial activity of prenylated flavonoids from Erythrina fusca. J Nat Prod. 2008;71:217–20.

37. Muiva LM, Yenesew A, Derese S, Heydenreich M, Peter MG, Akala HM. Antiplasmodial B-hydroxydihydrochalcone from seedpods of Tephrosia australis. Phytochem Lett. 2009; doi:10.1016/j.phytot.2009.01.002.

38. Oshimi S, Tomizawa Y, Hirasawa Y, Honda T, Ekasari W, Widyawaruyanti A. Chrobiostamine a, a new bischomeone from Cassia siamea and a biomimetic transformation of 5-acetyl-7-hydroxy-2-methylchromone into cassiarin a. Bioorg Med Chem Lett. 2008;18:3761–3.

39. Zelfack F, Gallet D, Fabre N, Bayet C, Chevalley S, Ngouela S, et al. Cytoxic and antiplasmodial xanthones from Pentadensia putaxaceus. J Nat Prod. 2009;72:954–7.

40. Ziegler HL, Hansen HS, Stærk D, Christensen SB, Hagerstrand H, Jaroszewski JW. The antiparasitic compound iccocalchone is a potent echinocytogenetic agent that modifies the erythrocyte membrane in the concentration range where antiplasmodial activity is observed. Antimicrob Agents Chemother. 2004;48:4067–71.

41. Ramanandrabe V, Geller P, Martin MT, Deville A, Joyeau R, Ramanitrahasimbola D, et al. Antiplasmodial phenolic compounds from Platanodendron. Planta Med. 2008;74:417–21.

42. Flores N, Jimenez IA, Gimenez A, Ruiz G, Gutierrez D, Bourdy G. Antiparasitic activity of prenylated benzoic acid derivatives from Piper species. Phytochemistry. 2009;70:217–22.

43. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev. Immunol. 2004;22:287–317.

44. Su Z, Fortin A, Gros P, Stevenson MM. Opsonin-independent phagocytosis: a new effector mechanism against acute blood-stage Plasmodium chabaudi AS infection. Infect Immun. 1983;39:1165–70.

45. Trubowitz S, Masek B. Fate of haem iron in the malaria parasite Plasmodium falciparum. Biochem J. 2002;365:343–7.

46. Sullivan D, Gluzman I, Russell D, Goldberg D. On the molecular mechanism of chloroquine’s antimalarial action. P Natl Acad Sci USA. 1996;93:11865–70.

47. Chowdhury A, Islam MS. Antibacterial activity of Tremaorientalis. Dhaka Univ J Pharm Sci. 2004;3:115–7.

48. Adinortey MB, Galuvuk IK, Asamoah NO. Trema Orientalis Linn. Blume: a potential for prospecting for drugs for various uses. Pharmacogn Rev. 2013(7):67–72.

49. Ogunkoya L, Olubajo OD, Sondha DS. A new triterpenoid alcohol from Trema orientalis. Phytochemistry. 1977;16:1606–8.

50. Uddin SN, Uddin KMA, Ahmed F. Alkalogenic and antidiarrhoal activities of Tremaorientalis Linn. In mice. Orl Pharm Exptal Med. 2008;8:187–91.

51. Ayensu ES. Medicinal plants of West Africa. Nordic J Bot. 1978;4:1–3.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit